This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2017 Feb 20;14(3):135-136.

doi: 10.1038/nrclinonc.2017.18.

Approvals in 2016: questioning the clinical benefit of anticancer therapies

Christopher M Booth¹, Joseph C Del Paggio²

Affiliations

Affiliations

¹ Departments of Oncology and Public Health Sciences, Queen's University, University Avenue, Kingston, Ontario K7L 3N6, Canada.
² Department of Medicine, Division of Medical Oncology, University of Toronto, King's College Circus, Toronto, Ontario M5S, Canada.

PMID: 28218259
DOI: 10.1038/nrclinonc.2017.18

Approvals in 2016: questioning the clinical benefit of anticancer therapies

Christopher M Booth et al. Nat Rev Clin Oncol. 2017.

. 2017 Feb 20;14(3):135-136.

doi: 10.1038/nrclinonc.2017.18.

Authors

Christopher M Booth¹, Joseph C Del Paggio²

Affiliations

¹ Departments of Oncology and Public Health Sciences, Queen's University, University Avenue, Kingston, Ontario K7L 3N6, Canada.
² Department of Medicine, Division of Medical Oncology, University of Toronto, King's College Circus, Toronto, Ontario M5S, Canada.

PMID: 28218259
DOI: 10.1038/nrclinonc.2017.18

No abstract available

PubMed Disclaimer

Similar articles

Approvals in 2016: cost-benefit challenges of new anticancer agents.
Savage P. Savage P. Nat Rev Clin Oncol. 2017 Feb 20;14(3):133-134. doi: 10.1038/nrclinonc.2017.12. Nat Rev Clin Oncol. 2017. PMID: 28218257 No abstract available.
Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
[No authors listed] [No authors listed] J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx173. J Natl Cancer Inst. 2017. PMID: 29117395 No abstract available.
Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies.
Whittington MD, McQueen RB, Campbell JD. Whittington MD, et al. JAMA Pediatr. 2018 May 1;172(5):409-410. doi: 10.1001/jamapediatrics.2018.0049. JAMA Pediatr. 2018. PMID: 29554182 No abstract available.
Patient-reported outcomes supporting anticancer product approvals.
Rock EP, Kennedy DL, Furness MH, Pierce WF, Pazdur R, Burke LB. Rock EP, et al. J Clin Oncol. 2007 Nov 10;25(32):5094-9. doi: 10.1200/JCO.2007.11.3803. J Clin Oncol. 2007. PMID: 17991927 Review.
Assessing tumor-related signs and symptoms to support cancer drug approval.
Williams G, Pazdur R, Temple R. Williams G, et al. J Biopharm Stat. 2004 Feb;14(1):5-21. doi: 10.1081/BIP-120028503. J Biopharm Stat. 2004. PMID: 15027497 Review.

See all similar articles

Cited by

The Making of Leukemia.
González-Herrero I, Rodríguez-Hernández G, Luengas-Martínez A, Isidro-Hernández M, Jiménez R, García-Cenador MB, García-Criado FJ, Sánchez-García I, Vicente-Dueñas C. González-Herrero I, et al. Int J Mol Sci. 2018 May 17;19(5):1494. doi: 10.3390/ijms19051494. Int J Mol Sci. 2018. PMID: 29772764 Free PMC article. Review.
Patient-reported outcomes in cancer care - hearing the patient voice at greater volume.
LeBlanc TW, Abernethy AP. LeBlanc TW, et al. Nat Rev Clin Oncol. 2017 Dec;14(12):763-772. doi: 10.1038/nrclinonc.2017.153. Epub 2017 Oct 4. Nat Rev Clin Oncol. 2017. PMID: 28975931 Review.
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit.
Schirrmacher V, Sprenger T, Stuecker W, Van Gool SW. Schirrmacher V, et al. Biomedicines. 2020 Jul 23;8(8):237. doi: 10.3390/biomedicines8080237. Biomedicines. 2020. PMID: 32717895 Free PMC article.
Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A, Schmitt AM, Speich B, Naudet F, Agarwal A, Pereira TV, Sclafani F, Herbrand AK, Briel M, Martin-Liberal J, Schmid T, Ewald H, Ioannidis JPA, Bucher HC, Kasenda B, Hemkens LG. Ladanie A, et al. JAMA Netw Open. 2020 Nov 2;3(11):e2024406. doi: 10.1001/jamanetworkopen.2020.24406. JAMA Netw Open. 2020. PMID: 33170262 Free PMC article.
Methods and Designs of Modern Breast Cancer Confirmatory Trials.
Péron J, Reverdy T, Smenteck C, Cortet M, You B, Freyer G. Péron J, et al. Cancers (Basel). 2021 Jun 2;13(11):2757. doi: 10.3390/cancers13112757. Cancers (Basel). 2021. PMID: 34199352 Free PMC article.

See all "Cited by" articles

References

1. N Engl J Med. 2015 Feb 12;372(7):621-30 - PubMed
1. J Clin Oncol. 2016 Aug 20;34(24):2925-34 - PubMed
1. Ann Oncol. 2015 Aug;26(8):1547-73 - PubMed
1. Ann Oncol. 2010 Jul;21(7):1411-8 - PubMed
1. Lancet. 2016 Jul 30;388(10043):488-97 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations